Sana Biotechnology Inc. (SANA)
Bid | 2.25 |
Market Cap | 512.4M |
Revenue (ttm) | n/a |
Net Income (ttm) | -290.03M |
EPS (ttm) | -1.16 |
PE Ratio (ttm) | -1.98 |
Forward PE | -3.45 |
Analyst | Buy |
Ask | 2.32 |
Volume | 10,048,004 |
Avg. Volume (20D) | 7,431,806 |
Open | 2.82 |
Previous Close | 2.77 |
Day's Range | 2.13 - 2.85 |
52-Week Range | 1.52 - 10.50 |
Beta | 1.64 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...
Analyst Forecast
According to 6 analyst ratings, the average rating for SANA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 292.16% from the latest price.
Stock Forecasts
2 months ago · proactiveinvestors.com
Sana Biotechnology skyrockets 200% on positive diabetes study dataSana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's ...

2 months ago · seekingalpha.com
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy SuccessSana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells...

2 months ago · https://thefly.com
Citi keeps $15 target on Sana, says data 'potentially transformative'Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the...

2 months ago · https://thefly.com
H.C. Wainwright ups Sana target after 'best case scenario' dataH.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based o...